Comparative Pharmacology
Head-to-head clinical analysis: MYZILRA versus UBRELVY.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MYZILRA versus UBRELVY.
MYZILRA vs UBRELVY
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
MYZILRA is a monoclonal antibody that binds to the neonatal Fc receptor (FcRn), reducing IgG recycling and lowering circulating IgG levels, including pathogenic autoantibodies.
Calcitonin gene-related peptide (CGRP) receptor antagonist; blocks CGRP-mediated vasodilation and nociception.
10 mg intravenously once daily for 12 weeks, followed by 10 mg subcutaneously every 8 weeks for maintenance.
100 mg orally once, may repeat once after at least 2 hours if needed; maximum 200 mg per 24 hours.
None Documented
None Documented
Terminal elimination half-life is 22 hours; permits once-daily dosing in most patients.
Terminal elimination half-life is approximately 50 hours, supporting once-daily dosing.
Renal elimination of unchanged drug accounts for 70% of clearance; biliary/fecal excretion accounts for 25%; 5% metabolized.
Primarily hepatic metabolism via CYP3A4, with 42% of dose excreted in feces (6% unchanged) and 26% in urine (1% unchanged).
Category C
Category C
CGRP Antagonist
CGRP Antagonist